InMed Pharmaceuticals (INM) Cash from Operations (2019 - 2026)

InMed Pharmaceuticals' Cash from Operations history runs 8 years deep, the most recent figure standing at 1695136.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 2.15% year-over-year to 1695136.0 in Q1 2026; TTM through Mar 2026 was 7457501.0, a 6.27% decrease from a year earlier, with the FY2025 full-year figure at 7766951.0, down 11.18% from the prior year.
• Cash from Operations advanced to 1695136.0 in Q1 2026 per INM's latest filing, from 2376243.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 657934.0 in Q2 2023 and bottomed at 5348786.0 in Q1 2022.
• The 5-year median for Cash from Operations is 1848133.0 (2023), against an average of 2183000.59.
• Across the five-year window, Cash from Operations sank 101.75% in 2022 and jumped 83.74% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 2713096.0 in 2022, then surged by 31.88% to 1848133.0 in 2023, then tumbled by 35.39% to 2502138.0 in 2024, then grew by 5.03% to 2376243.0 in 2025, then increased by 28.66% to 1695136.0 in 2026.
• Per Business Quant, the three latest INM Cash from Operations figures stand at 1695136.0 (Q1 2026), 2376243.0 (Q4 2025), and 1607616.0 (Q3 2025).